Exploring a new pathway for biomarker-based approval of immunotherapies

Nature Reviews Clinical Oncology, Published online: 27 January 2023; doi:10.1038/s41571-023-00731-8The revolution of immunotherapies in oncology has not been matched by the development of companion diagnostic biomarkers able to identify the ideal target populations. Aside from the established pathways for regulatory approval relying on predefined biomarkers, a novel approach based on post hoc biomarker analysis could potentially be instrumental in enhancing the cost-effectiveness of cancer immunotherapy.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research